Study Finds Modest Link Between Semaglutide and a Type of Vision Impairment

As glucagon-like peptide-1 (GLP-1) receptor agonists continue to rise in popularity as a treatment option for individuals with type 2 diabetes (T2D), their potential connection to vision problems has raised concern. A study published in JAMA Ophthalmology suggests that there is an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) with semaglutide use in people with T2D.